Journal Article10.1080/09553002.2020.1838655
Overall survival in mCPRC patients treated with Radium-223 in association with bone health agents: a national multicenter study.
Viviana Frantellizzi,Fabio Monari,Manlio Mascia,Renato Costa,Giuseppe Rubini,Angela Spanu,Alessio Farcomeni,Elisa Lodi Rizzini,Luca Cindolo,Maria Licari,Valentina Lavelli,Susanna Nuvoli,Maria Antonietta Ricci,Valeria Dionisi,Anna Giulia Nappi,Giuseppe De Vincentis +15 more
9
TL;DR: The results support and confirm the role of Radium-223 therapy on OS and, furthermore, appear to confirm that BHA treatment has not a survival benefit.
read more
Abstract: Radium-223 has demonstrated efficacy in improving overall survival (OS) and in delaying symptomatic skeletal-related events (SREs). Bone Health Agents (BHA), i.e. RANK ligand inhibitor (Denosumab) ...
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Association between adiposity after diagnosis of prostate cancer and mortality: systematic review and meta-analysis
Margarita Cariolou,Georgios Markozannes,Nerea Becerra-Tomás,Rita Vieira,Katia Balducci,Dagfinn Aune,David Miller,Doris S. M. Chan,Konstantinos K. Tsilidis +8 more
TL;DR: In this paper , the authors explored the associations between adiposity indices, assessed at or after a diagnosis of prostate cancer, and mortality and found that patients with prostate cancer might benefit from maintaining a healthy weight and avoiding obesity.
The DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl2: A Multicenter Italian Study
Maria Silvia De Feo,Viviana Frantellizzi,Matteo Bauckneht,Alessio Farcomeni,Luca Filippi,E. Lodi Rizzini,Valentina Lavelli,Maria Lina Stazza,Tania Di Raimondo,Giuseppe Fornarini,Sara Elena Rebuzzi,P. Mammucci,Andrea Marongiu,Fabio Monari,Giuseppe Rubini,Angela Spanu,Giuseppe De Vincentis +16 more
TL;DR: In this article , the impact of baseline bone scan index (BSI) on overall survival (OS) in mCRPC patients treated with Radium-223 dichloride (223RaCl2) was assessed.
Therapy of bone metastases with alpha emitters
01 Jan 2022
TL;DR: Radium-223 is a calcium analog α-emitter radioisotope that accumulates in osteoblastic bone metastases, causing cell death by promoting a complete and irreversible breakage of both DNA strands as discussed by the authors .
Zoledronic Acid Prevents Bone Resorption Caused by the Combination of Radium-223, Abiraterone Acetate, and Prednisone in an Intratibial Prostate Cancer Mouse Model
Mari I. Suominen,Matti Knuuttila,Birgitta Sjöholm,Timothy G Wilson,Esa Alhoniemi,Dominik Mumberg,Sanna-Maria Käkönen,Arne Scholz +7 more
TL;DR: Evaluated the efficacy and potential bone health-related effects of radium-223, abiraterone acetate, prednisone, and zoledronic acid as monotherapies or combinations in an intratibial LNCaP prostate cancer xenograft model mimicking bone metastatic prostate cancer to identify mechanisms leading to an increased fracture risk.
Evaluation of bone scan index as a prognostic tool in breast cancer patients with bone metastasis.
Maria Silvia De Feo,Viviana Frantellizzi,Arianna Di Rocco,Alessio Farcomeni,Andrea Marongiu,Antonio Matto,Susanna Nuvoli,Angela Spanu,Giuseppe De Vincentis +8 more
TL;DR: In this paper , the authors used the Bone Scan Index (BSI) which is a reproducible and quantitative expression of tumor load observed at bone scintigraphy to associate BSI with OS in bone metastatic BC patients.
References
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Chris Parker,Sten Nilsson,Sten Nilsson,D. Heinrich,Svein Inge Helle,Joe M. O'Sullivan,Sophie D. Fosså,Ales Chodacki,Paweł Wiechno,John P Logue,Mihalj Seke,Anders Widmark,D. C. Johannessen,Peter Hoskin,David Bottomley,Nicholas D. James,Arne Solberg,Isabel Syndikus,Ján Kliment,S. Wedel,S. Boehmer,Marcos F. Dall'Oglio,Lars Franzén,Robert E. Coleman,Nicholas J. Vogelzang,C.G. O'Bryan-Tear,K. Staudacher,J. Garcia-Vargas,M. Shan,Øyvind S. Bruland,Oliver Sartor +30 more
TL;DR: In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival and was associated with low myelosuppression rates and fewer adverse events.
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Matthew R. Smith,Chris Parker,Fred Saad,Kurt Miller,Bertrand Tombal,Quan Sing Ng,Martin Boegemann,Vsevolod Matveev,Josep M. Piulats,Luis Eduardo Zucca,Oleg Karyakin,Go Kimura,Nobuaki Matsubara,William C. Nahas,Franco Nolè,Eli Rosenbaum,Axel Heidenreich,Yoshiyuki Kakehi,Amily Zhang,Heiko Krissel,Michael Teufel,Junwu Shen,Volker Wagner,Celestia S. Higano +23 more
TL;DR: Concurrent treatment with abiraterone acetate plus prednisone or prednisolone and radium-223 improves overall survival and delays the onset of symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases.
355
Prognostic Significance of Extent of Disease in Bone in Patients With Androgen-Independent Prostate Cancer
Paul Sabbatini,Steven M. Larson,A. B. Kremer,Zuo-Feng Zhang,Maxine Sun,Henry Yeung,Massimo Imbriaco,I. D. Horak,M. Conolly,C. Ding,P. Ouyang,Wm. Kevin Kelly,Howard I. Scher +12 more
TL;DR: The BSI quantifies the extent of skeletal involvement by tumor and allows the identification of patients with distinct prognoses for stratification in clinical trials and may be particularly useful in the evaluation of agents for which prostate-specific antigen changes do not reflect clinical outcomes accurately.
234
Quality of life after palliative radiation therapy for patients with painful bone metastases: results of an international study validating the EORTC QLQ-BM22.
Liang Zeng,Edward Chow,Gillian Bedard,Liying Zhang,Alysa Fairchild,Vassilios Vassiliou,Mohamed A. Alm El-Din,Reynaldo Jesus-Garcia,Aswin Kumar,Fabien Forges,Ling-Ming Tseng,Ming-Feng Hou,Wei-Chu Chie,Andrew Bottomley +13 more
TL;DR: Patients who report pain relief after palliative RT also have better QOL with respect to bone metastasis-specific issues, and the QLQ-BM22 and QL-C30 are able to discriminate among patients with varying responses and are recommended for use in futureBone metastasis clinical trials.
89
Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial
Nicholas D. James,Sarah Pirrie,Ann Pope,Darren Barton,Lazaros Andronis,Ilias Goranitis,Stuart Collins,Adam Daunton,Duncan McLaren,Joe M. O'Sullivan,Chris Parker,Emilio Porfiri,John Staffurth,Andrew Stanley,James D. Wylie,Sharon Beesley,Alison Birtle,Janet E. Brown,Prabir Chakraborti,Syed A. Hussain,Martin J. Russell,Lucinda Billingham +21 more
TL;DR: Clinical effectiveness and cost-effectiveness of combining docetaxel, ZA, and Sr89, all having palliative benefits and used in bony metastatic CRPC to control bone symptoms and, for docetAXel, to prolong survival were determined.
81
Related Papers (5)
Chris Parker,D. Heinrich,Svein Inge Helle,J.M O'Sullivan,Sophie D. Fosså,Ales Chodacki,Tomasz Demkow,John P Logue,Mihalj Seke,Anders Widmark,D.C. Johannessen,Stinabritt Nilsson,Peter Hoskin,David Bottomley,Arne Solberg,Nicholas D. James,Isabel Syndikus,S. Wedel,Ján Kliment,A. Cross,C.G. O'Bryan-Tear,J. Garcia-Vargas,Oliver Sartor +22 more